Nuvectis Pharma, Inc. (NVCT) Financial Statements (2026 and earlier)
Company Profile
| Business Address |
1 BRIDGE PLAZA, SUITE 275 FORT LEE, NJ 07024 |
| State of Incorp. | DE |
| Fiscal Year End | December 31 |
| Industry (SIC) | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) (USD)
| 12/31/2025 | 12/31/2024 | 12/31/2023 | 12/31/2022 | |||
|---|---|---|---|---|---|---|
| ASSETS | ||||||
| Current Assets | ||||||
| Cash, cash equivalents, and short-term investments | 18,533,000 | 19,126,000 | 19,993,000 | |||
| Cash and cash equivalent | 18,533,000 | 19,126,000 | 19,993,000 | |||
| Other current assets | 74,000 | 59,000 | 412,000 | |||
| Total current assets: | 18,607,000 | 19,185,000 | 20,405,000 | |||
| Noncurrent Assets | ||||||
| TOTAL ASSETS: | 18,607,000 | 19,185,000 | 20,405,000 | |||
| LIABILITIES AND EQUITY | ||||||
| Liabilities | ||||||
| Current Liabilities | ||||||
| Accounts payable and accrued liabilities | 3,338,000 | 3,186,000 | 5,736,000 | |||
| Employee-related liabilities | ✕ | ✕ | ✕ | 2,381,000 | ||
| Accounts payable | 2,498,000 | 2,771,000 | 2,910,000 | |||
| Accrued liabilities | 840,000 | 415,000 | 445,000 | |||
| Other undisclosed current liabilities | 5,556,000 | 3,798,000 | 450,000 | |||
| Total current liabilities: | 8,894,000 | 6,984,000 | 6,186,000 | |||
| Noncurrent Liabilities | ||||||
| Total liabilities: | 8,894,000 | 6,984,000 | 6,186,000 | |||
| Equity | ||||||
| Equity, attributable to parent | 9,713,000 | 12,201,000 | 14,219,000 | |||
| Additional paid in capital | 82,958,000 | 66,446,000 | 46,204,000 | |||
| Accumulated deficit | (73,245,000) | (54,245,000) | (31,985,000) | |||
| Total equity: | 9,713,000 | 12,201,000 | 14,219,000 | |||
| TOTAL LIABILITIES AND EQUITY: | 18,607,000 | 19,185,000 | 20,405,000 | |||
Income Statement (P&L) (USD)
| 12/31/2025 | 12/31/2024 | 12/31/2023 | 12/31/2022 | ||
|---|---|---|---|---|---|
| Gross profit: | (1,535,000) | (3,495,000) | (2,170,000) | ||
| Operating expenses | (19,847,000) | (22,897,000) | (19,234,000) | ||
| Other undisclosed operating income | 1,535,000 | 3,495,000 | 2,170,000 | ||
| Operating loss: | (19,847,000) | (22,897,000) | (19,234,000) | ||
| Loss from continuing operations: | (19,847,000) | (22,897,000) | (19,234,000) | ||
| Other undisclosed net income | 847,000 | 637,000 | 149,000 | ||
| Net loss attributable to parent: | (19,000,000) | (22,260,000) | (19,085,000) | ||
| Other undisclosed net loss available to common stockholders, basic | |||||
| Net loss available to common stockholders, diluted: | (19,000,000) | (22,260,000) | (19,085,000) | ||
Comprehensive Income (USD)
| 12/31/2025 | 12/31/2024 | 12/31/2023 | 12/31/2022 | ||
|---|---|---|---|---|---|
| Net loss: | (19,000,000) | (22,260,000) | (19,085,000) | ||
| Comprehensive loss, net of tax, attributable to parent: | (19,000,000) | (22,260,000) | (19,085,000) | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.